Technical Analysis for RZLT - Rezolute, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -1.12% | |
| Wide Bands | Range Expansion | -1.12% | |
| 20 DMA Resistance | Bearish | -7.02% | |
| Wide Bands | Range Expansion | -7.02% | |
| 20 DMA Resistance | Bearish | -11.37% | |
| Earnings Movers | Other | -11.37% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 14 hours ago |
| Possible NR7 | about 15 hours ago |
| Up 2% | about 16 hours ago |
| Up 1% | about 19 hours ago |
| Fell Below Previous Day's Low | about 19 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. Its products include RZ358, a human monoclonal antibody that is in Phase II clinical trial for the treatment of congenital hyperinsulinism, a devastating ultra-orphan pediatric disease; and RZ402, a plasma kallikrein inhibitor, which is in late stage preclinical program for the treatment of diabetic macular edema. It also develops AB101, a human recombinant insulin, which is in Phase I clinical trial for the treatment of patients with type 1 and type 2 diabetes mellitus. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Life Sciences Diabetes Cancer Treatment Monoclonal Antibody Insulin Metabolic Disease Specialty Drugs Diabetes Mellitus Diabetic Retinopathy Macular Edema Diabetic Macular Edema Kallikrein Plasma Kallikrein
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Life Sciences Diabetes Cancer Treatment Monoclonal Antibody Insulin Metabolic Disease Specialty Drugs Diabetes Mellitus Diabetic Retinopathy Macular Edema Diabetic Macular Edema Kallikrein Plasma Kallikrein
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.69 |
| 52 Week Low | 0.72 |
| Average Volume | 271,684 |
| 200-Day Moving Average | 1.50 |
| 50-Day Moving Average | 2.52 |
| 20-Day Moving Average | 2.94 |
| 10-Day Moving Average | 2.94 |
| Average True Range | 0.30 |
| RSI (14) | 46.52 |
| ADX | 35.58 |
| +DI | 21.42 |
| -DI | 16.71 |
| Chandelier Exit (Long, 3 ATRs) | 2.79 |
| Chandelier Exit (Short, 3 ATRs) | 3.40 |
| Upper Bollinger Bands | 3.49 |
| Lower Bollinger Band | 2.38 |
| Percent B (%b) | 0.25 |
| BandWidth | 38.09 |
| MACD Line | 0.06 |
| MACD Signal Line | 0.13 |
| MACD Histogram | -0.0664 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.86 | ||||
| Resistance 3 (R3) | 2.87 | 2.81 | 2.83 | ||
| Resistance 2 (R2) | 2.81 | 2.76 | 2.81 | 2.81 | |
| Resistance 1 (R1) | 2.73 | 2.72 | 2.77 | 2.72 | 2.80 |
| Pivot Point | 2.67 | 2.67 | 2.69 | 2.67 | 2.67 |
| Support 1 (S1) | 2.59 | 2.62 | 2.63 | 2.58 | 2.50 |
| Support 2 (S2) | 2.53 | 2.58 | 2.53 | 2.49 | |
| Support 3 (S3) | 2.45 | 2.53 | 2.48 | ||
| Support 4 (S4) | 2.44 |
